ACLX: Arcellx Inc. Stocks News on October 29, 2025

Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock.

ACLX

Barrons.com

a month ago

Gilead’s Lost Decade Is Over. It’s Time to Buy the Stock.

ACLX

MT Newswires

a month ago

Arcellx Insider Sold Shares Worth $1,709,723, According to a Recent SEC Filing

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

ACLX

BioPharma Dive

2 months ago

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma

ACLX

Clinical Trials Arena

4 months ago

EHA 2025: Anito-cel to disrupt CAR-T market in multiple myeloma

ACLX

MT Newswires

4 months ago

Citigroup Initiates Arcellx at Buy With $110 Price Target

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

ACLX

Business Wire

5 months ago

Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025

ACLX

Insider Monkey

5 months ago

Baron Discovery Fund Initiated a Position in Arcellx (ACLX)

ACLX

MT Newswires

5 months ago

Arcellx's Potential Multiple Myeloma Treatment Shows 97% Overall Response Rate in Phase 2 Study; Shares Rise

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma$

ACLX

Business Wire

5 months ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma

ACLX

Insider Monkey

6 months ago

Here’s Why Arcellx (ACLX) Declined in Q1

Arcellx First Quarter 2025 Earnings: Misses Expectations

ACLX

Simply Wall St.

6 months ago

Arcellx First Quarter 2025 Earnings: Misses Expectations

ACLX

Zacks

6 months ago

Arcellx, Inc. (ACLX) Reports Q1 Loss, Lags Revenue Estimates

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

ACLX

Business Wire

6 months ago

Arcellx Provides First Quarter 2025 Financial Results and Business Highlights

ACLX

Insider Monkey

6 months ago

Arcellx, Inc. (ACLX): Among Takeover Rumors Hedge Funds Are Buying

ACLX

Insider Monkey

7 months ago

Arcellx (ACLX): Among Billionaire Stanley Druckenmiller’s Top Stock Picks with Huge Upside Potential

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

ACLX

Business Wire

7 months ago

Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

ACLX

Simply Wall St.

8 months ago

We're Not Worried About Arcellx's (NASDAQ:ACLX) Cash Burn

ACLX

Zacks

8 months ago

Arcellx, Inc. (ACLX) Reports Q4 Loss, Lags Revenue Estimates

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

ACLX

Business Wire

8 months ago

Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights

ACLX

MT Newswires

8 months ago

Arcellx Insider Sold Shares Worth $2,375,517, According to a Recent SEC Filing

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

ACLX

Business Wire

8 months ago

Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference

ACLX

Insider Monkey

8 months ago

Is Arcellx, Inc. (ACLX) An Oversold Biotech Stock to Buy Now?

ACLX

Insider Monkey

8 months ago

Is Arcellx (ACLX) Poised to Capture Significant Market Share?

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

ACLX

Zacks

9 months ago

Adaptive Biotechnologies (ADPT) Soars 18.0%: Is Further Upside Left in the Stock?

ACLX

Argus Research

10 months ago

Daily – Vickers Top Buyers & Sellers for 01/13/2025

ACLX

MT Newswires

10 months ago

Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing

ACLX

MT Newswires

10 months ago

Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing

Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?

ACLX

Zacks

10 months ago

Guardant Health (GH) Soars 6.3%: Is Further Upside Left in the Stock?

ACLX

MT Newswires

10 months ago

Arcellx Insider Sold Shares Worth $2,244,896, According to a Recent SEC Filing

Arcellx Stock Earns 82 Relative Strength Rating

ACLX

Investor's Business Daily

10 months ago

Arcellx Stock Earns 82 Relative Strength Rating

ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma

ACLX

Clinical Trials Arena

a year ago

ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma

ACLX

MT Newswires

a year ago

Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says

ACLX

MT Newswires

a year ago

UBS Raises Price Target on Arcellx to $114 From $106, Maintains Buy Rating

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

ACLX

Investor's Business Daily

a year ago

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

ACLX

MT Newswires

a year ago

Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday

ACLX

MT Newswires

a year ago

Sector Update: Health Care

ACLX

Benzinga

a year ago

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

ACLX

MT Newswires

a year ago

Arcellx Says Trial of Multiple Myeloma Drug Candidate Achieves 97% Overall Response Rate

$Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition$

ACLX

Business Wire

a year ago

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

ACLX

Zacks

a year ago

Are You Looking for a Top Momentum Pick? Why Arcellx, Inc. (ACLX) is a Great Choice

ACLX

MT Newswires

a year ago

Arcellx Insider Sold Shares Worth $1,242,170, According to a Recent SEC Filing

Arcellx Third Quarter 2024 Earnings: Misses Expectations

ACLX

Simply Wall St.

a year ago

Arcellx Third Quarter 2024 Earnings: Misses Expectations

ACLX

Zacks

a year ago

Is Arcellx (ACLX) Outperforming Other Medical Stocks This Year?

ACLX

Zacks

a year ago

Arcellx, Inc. (ACLX) Reports Q3 Loss, Lags Revenue Estimates

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

ACLX

Business Wire

a year ago

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx price target raised to $106 from $81 at Morgan Stanley

ACLX

TipRanks

a year ago

Arcellx price target raised to $106 from $81 at Morgan Stanley

ACLX

Zacks

a year ago

Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?

ACLX

MT Newswires

a year ago

Morgan Stanley Adjusts Arcellx's Price Target to $106 From $81, Keeps Overweight Rating

$Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study$